Overview

Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase II study of the drug combination of Oxaliplatin, Avastin and capecitabine. This is an open-label study.
Phase:
Phase 2
Details
Lead Sponsor:
University of Pittsburgh
Collaborator:
Genentech, Inc.
Treatments:
Bevacizumab
Capecitabine
Oxaliplatin